
Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma
The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows a dosing frequency of 1.5 mg/kg every 2 weeks.
Johnson & Johnson
The therapy, given subcutaneously, was first approved in
According to a statement from Johnson & Johnson, teclistamab has been prescribed to more than 3600 patients in the United States since its approval. This latest approval is based results for a group of patients in the phase 1/2 MajesTEC-1 study (
“[Teclistamab] is the only BCMA-targeted immune-based therapy with weight-based dosing,” Rachel Kobos, MD, vice president, Oncology Research & Development, Johnson & Johnson Innovative Medicine, said
Adverse events from teclistamab can include cytokine release syndrome and neurologic toxicity, including immune effector cell–associated neurotoxicity syndrome.
Reference
Tecvayli (teclistamab-cqyv) biweekly dosing approved by the US FDA for the treatment of patients with relapsed or refractory multiple myeloma. News release. Johnson & Johnson. February 20, 2024. Accessed February 23, 2024.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.